Association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) Genetic Polymorphisms and Venous Thromboembolism in Cancer Patients

Abstract

Objectives: to assess the relationship between TSPAN15 and SLC44A2 polymorphisms and VTE in cancer patients was evaluated with correlation to PROTECHT scoring system and survival data. Background: Although venous thromboembolism (VTE) is common in cancer patients, the underlying mechanisms are complex and poorly understood. .Methods: This study enrolled two groups: 50 VTE-cancer patients in group I and 50 cancer patients with no VTE in group II. Full history, general examination, histopathological diagnosis, and clinical stage were recorded. Complete blood count, coagulation profile, and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by polymerase chain reaction technique were done. Radiological examinations was done according to the clinical scenario. PROTECHT score and survival analysis were performed. Results: VTE-cancer patients had high grade cancer, increased incidence of metastasis with shorter progression-free survival (PFS) versus those without VTE. Partial immobilization, hospitalization and gemcitabine-based chemotherapy showed a significant relationship with VTE in cancer patients. SLC44A2 and TSPAN15 mutant alleles were more prevalent in group I. SLC44A2 (AG+GG) and TSPAN15 (CC) genotypes were identified as VTE independent risk factors. Conclusion: VTE is associated with higher tumor grades and metastatic disease, and it is linked to shorter PFS in cancer patients. Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.